Search Results - "D'Cruz, DP"

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE by Dooley, MA, Houssiau, F, Aranow, C, D’Cruz, DP, Askanase, A, Roth, DA, Zhong, ZJ, Cooper, S, Freimuth, WW, Ginzler, EM

“…A pooled post-hoc analysis of the phase 3, randomized, placebo-controlled BLISS trials (1684 patients with active systemic lupus erythematosus (SLE)) was…”
Get full text

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis by Davies, RJ, Sangle, SR, Jordan, NP, Aslam, L, Lewis, MJ, Wedgwood, R, D’Cruz, DP

“…Objective *Deceased.The objective of this paper is to report the clinical outcome of B cell depletion therapy in 18 patients with refractory lupus nephritis…”
Get full text

Systemic lupus erythematosus by D'Cruz, David P

“…Systemic lupus erythematosus (SLE) is a multisystem autoimmune connective tissue disorder. It is prevalent among young women with a peak age of onset between…”
Get full text

Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids by Davies, RJ, Lomer, MCE, Yeo, SI, Avloniti, K, Sangle, SR, D’Cruz, DP

“…Background: Patients with systemic lupus erythematosus (SLE) may require prolonged periods of corticosteroid therapy which lead to excessive weight gain and…”
Get full text

Increased risk of vascular complications in Takayasu's arteritis patients with positive lupus anticoagulant by Jordan, NP, Bezanahary, H, D'Cruz, DP

“…Objectives: Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical…”
Get full text

Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative by Lampropoulos, C. E., Sangle, S., Harrison, P., Hughes, G. R. V., D'Cruz, D. P.

“…Objective. To determine the efficacy of tacrolimus ointment 0.1% on resistant cutaneous lesions in patients with lupus erythematosus. Methods. Twelve patients…”
Get full text

Correlation of 24-hour urinary protein quantification with spot urine protein:creatinine ratio in lupus nephritis by Matar, HE, Peterson, P, Sangle, S, D’Cruz, DP

“…Objectives: Twenty-four hour urine collection has been the foundation for monitoring patients with lupus nephritis. However, the use of protein to creatinine…”
Get full text

The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol by D’Cruz, DP, Houssiau, FA

“…The treatment of lupus nephritis has evolved over many decades and cyclophosphamide has become the standard of care for proliferative lupus nephritis. This…”
Get full text

Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? by Ferreira, S., D'Cruz, D. P., Hughes, G. R. V.

“…Multiple sclerosis (MS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are chronic, immune-mediated, relapsing–remitting disorders…”
Get full text

Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise by Tench, C. M., McCarthy, J., McCurdie, I., White, P. D., D'Cruz, D. P.

“…Objective. To test the efficacy of a graded aerobic exercise programme in treating fatigue in systemic lupus erythematosus. Methods. Ninety‐three patients with…”
Get full text

Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease good functional outcome and relevance of antiphospholipid antibodies by D'CRUZ, David P, MELLOR-PITA, Susana, JOVEN, Beatriz, SANNA, Giovanni, ALLANSON, Judith, TAYLOR, James, KHAMASHTA, Munther A, HUGHES, Graham R. V

“…Transverse myelitis (TM) is a rare complication of systemic lupus erythematosus (SLE). Although usually a late manifestation of SLE, it can occur at…”
Get full text

The prevalence and associations of fatigue in systemic lupus erythematosus by Tench, C. M., McCurdie, I., White, P. D., D'Cruz, D. P.

“…Objective. This study assessed the prevalence and associations of fatigue in systemic lupus erythematosus (SLE). Methods. Questionnaires were used to measure…”
Get full text

Renal manifestations of the antiphospholipid syndrome by D’Cruz, D P

“…Renal thrombotic manifestations have been reported since the earliest descriptions of the antiphospholipid (Hughes) syndrome (APS). The spectrum of clinical…”
Get full text

Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients by PISONI, Cecilia N, SANCHEZ, Francisco J, KARIM, Yousuf, CUADRADO, Maria J, D'CRUZ, David P, ABBS, Ian C, KHAMASHTA, Munther A, HUGHES, Graham R. V

“…OBJECTIVE: To assess the indications, efficacy, and tolerability of mycophenolate mofetil (MMF) in patients with systemic lupus erythematosus (SLE) resistant…”
Get full text

Mathematical analysis of antigen selection in somatically mutated immunoglobulin genes associated with autoimmunity by MacDonald, CM, Boursier, L., D'Cruz, DP, Dunn-Walters, DK, Spencer, J.

“…Affinity maturation is a process by which low-affinity antibodies are transformed into highly specific antibodies in germinal centres. This process occurs by…”
Get full text

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents by Karim, M. Y., Alba, P., Cuadrado, M.‐J., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V.

“…Background. Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used in solid organ transplantation, and it may play an increasing role in…”
Get full text

Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension by Sangle, S R, D’Cruz, D P, Jan, W, Karim, M Y, Khamashta, M A, Abbs, I C, Hughes, G R V

“…Background: Hypertension is common in the antiphospholipid (Hughes) syndrome (APS) and its cause is poorly understood. Anecdotal evidence suggests that renal…”
Get full text

Prevalence of the antiphospholipid syndrome in primary systemic vasculitis by Rees, J D, Lança, S, Marques, P V, Gómez-Puerta, J A, Moco, R, Oliveri, C, Khamashta, M A, Hughes, G R V, D’Cruz, D P

“…Background: The antiphospholipid (APS or Hughes’) syndrome, anticardiolipin antibodies (aCL), and the lupus anticoagulant (LA) are associated with systemic…”
Get full text

Mycophenolate mofetil in systemic vasculitis by D'cruz, DP

“…The systemic vasculitides are a group of potentially life-threatening multi-system autoimmune connective tissue diseases characterized by vascular…”
Get full text

Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data by Barón, M A, Khamashta, M A, Hughes, G R V, D’Cruz, D P

“…Objectives: To evaluate the prevalence of abnormal ankle-brachial indexes (ABIs), their relationship with other cardiovascular risk factors and/or the presence…”
Get full text